IOncology

Hepatocellular carcinoma (HCC), the most common primary malignant liver tumor, is one of the leading causes of death in patients with cirrhosis. Non-invasive diagnostic tools such as transient elastography (FibroScan) have shown great promise in identifying patients at high risk of HCC. Recently, the 2025 EASL Liver Cancer Summit was held in Paris, France. Professor Abdel Ghani Atef from the Damas Liver & G.I.T Center in Egypt presented research on the value of ultrasound elastography in the early detection of HCC in patients with cirrhosis. To this end, a journalist from Oncology Frontier traveled to the summit and invited Professor Abdel Ghani Atef to have an in-depth discussion on topics such as the role of FibroScan in HCC screening and the significance of liver stiffness measurement cutoff values.

A recent study published in JNCI Cancer Spectrum (Jan 2025) introduces a machine learning-based cancer-specific cardiovascular disease (CVD) risk score, designed to improve risk prediction for breast, colorectal, and lung…

A newly published study in ESMO Open (Jan 2025) led by H. S. Rugo, R. M. Layman, F. Lynce, G. Curigliano, A. Brufsky, and colleagues analyzed real-world overall survival (OS)…

From July 5th to 7th, the "2024 Annual Progress Seminar in Clinical Oncology in China (BOC)," hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO. Additionally, it focused on the theme of the 2024 ASCO Annual Meeting, "The Art and Science of Cancer Care: From Comfort to Cure," and discussed and interpreted major research presented at ASCO. To gain in-depth insights into the relevant content and trends, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Donglu Zhao from the Harbin Institute of Hematology and Oncology, who provided an excellent analysis of these topics.

From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the contributors to the "Annual Advances in Clinical Oncology Research in China," Professor Biyun Wang from Fudan University Shanghai Cancer Center also detailed the ACE-Breast-02 study at this conference, showcasing the rigor and innovation of Chinese research. "Oncology Frontier" interviewed Professor Biyun Wang, and the compilation is presented below.

Dr. Hans Wildiers and colleagues published findings from the AIPAC Phase IIb trial (Clin Cancer Res, Feb 2024), evaluating eftilagimod alpha (efti), a soluble LAG-3 protein, in combination with paclitaxel…

With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People's Liberation Army General Hospital shared insights on the committee members' demeanor, the crucial role of young doctors within the association, and experiences and advice for young doctors on their growth path. Drawing from his own experiences, Professor Jiang encouraged young doctors to seize opportunities, actively engage in clinical practice and research, and contribute to both personal and societal value. He also offered words of encouragement to students aspiring to enter the medical field, urging them to pursue their dreams and contribute to the advancement of medical science in China.

The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a study analyzed the efficacy of different immunotherapy combinations for mCRPC patients and examined potential biomarkers.

In the second part of their discussion at ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) examined the evolving…

At ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) discussed VHL-associated renal cell carcinoma (RCC) and the latest Belzutifan data.…